Liquidia Corporation

NasdaqCM:LQDA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 1.13 B

Share Price

USD 13.17

Avg Daily Volume

1,539,774

Change (1 day)

-3.45%

Change (1 year)

7.25%

Change (YTD)

11.99%

Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD 0.17

Liquidia Corporation Revenue Per Share is USD 0.17 for the Trailing 12 Months (TTM) ending March 31, 2025, a -26.19% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 0.24, a -10.83% change year over year.
Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.26.

Quarterly
Annual
TTM

From:

To:

Zoom:

1Y
3Y
5Y
10Y
15Y
20Y
Max

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	170
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Similar companies

Eli Lilly and Company

USD 762.73

-2.84%

AbbVie Inc.

USD 185.30

-0.10%

Roche Holding AG

USD 336.78

-0.52%

AstraZeneca PLC

USD 140.24

-1.30%

Merck & Co., Inc.

USD 79.06

-0.29%

Amgen Inc.

USD 289.33

-0.10%

Pfizer Inc.

USD 23.97

0.38%

Gilead Sciences, Inc.

USD 108.50

0.46%

Sanofi

USD 95.88

0.36%

Bristol-Myers Squibb Company

USD 46.86

0.04%

Chugai Pharmaceutical Co., Ltd.

USD 49.19

-0.68%

GSK plc

USD 18.89

-2.25%

Cencora, Inc.

USD 293.66

-1.04%

Regeneron Pharmaceuticals, Inc.

USD 509.72

-0.75%

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.23

0.75%

Haleon plc

USD 5.16

0.21%

Takeda Pharmaceutical Company Limited

USD 29.34

-0.64%

Daiichi Sankyo Company, Limited

USD 22.63

-2.53%

UCB SA

USD 181.46

0.14%

Hansoh Pharmaceutical Group Company Limited

USD 3.57

0.90%

Teva Pharmaceutical Industries Limited

USD 17.30

1.37%

Insmed Incorporated

USD 102.68

3.24%

West Pharmaceutical Services, Inc.

USD 215.82

-0.98%

Summit Therapeutics Inc.

USD 20.56

1.98%

Cipla Limited

USD 17.31

1.15%

United Therapeutics Corporation

USD 290.75

-0.33%

Dr. Reddy's Laboratories Limited

USD 15.30

0.03%

Torrent Pharmaceuticals Limited

USD 36.56

0.20%

Sino Biopharmaceutical Limited

USD 0.64

2.89%

Mankind Pharma Limited

USD 26.42

-1.47%

Zydus Lifesciences Limited

USD 11.05

0.84%

CSPC Pharmaceutical Group Limited

USD 0.97

0.13%

BioMarin Pharmaceutical Inc.

USD 55.00

-0.43%

Ascendis Pharma A/S

USD 176.90

3.63%

Viatris Inc.

USD 8.87

1.14%

Orion Oyj

USD 73.21

1.00%

Lupin Limited

USD 22.49

0.94%

Huadong Medicine Co., Ltd

USD 5.79

1.13%

Ipsen S.A.

USD 116.25

-0.06%

Swedish Orphan Biovitrum AB (publ)

USD 28.19

-3.10%

Kyowa Kirin Co., Ltd.

USD 16.98

-0.29%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

USD 1.97

-0.51%

Shanghai Pharmaceuticals Holding Co., Ltd

USD 1.46

0.70%

Eisai Co., Ltd.

USD 26.98

-1.46%

Abbott India Limited

USD 364.99

2.00%

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.75

-1.49%

Sinopharm Group Co. Ltd.

USD 2.35

0.88%

Shenzhen Salubris Pharmaceuticals Co., Ltd.

USD 6.55

-0.98%

Beijing Tongrentang Co., Ltd

USD 5.02

0.79%

Haisco Pharmaceutical Group Co., Ltd.

USD 5.72

-2.62%

StockViz Staff

June 23, 2025

Any question? Send us an email